Table 3.
The association between the demographic, clinical and laboratory variables and the MTHFR C677T polymorphisms in stroke patients.
| CT n = 81 |
CT + TT n = 92 |
CC n = 8 |
TT n = 11 |
Test (p) | P1 | Test (p) | P2 | |
|---|---|---|---|---|---|---|---|---|
| SBP (mmHg) | 130 (100–190) | 130 (90–190) | 135 (120–160) | 140 (90–160) | F = 0.553 | 0.577 | T = 0.960 | 0.339 |
| DBP (mmHg) | 80 (60–100) | 80 (50–100) | 80 (70–90) | 80 (50–100) | F = 0.739 | 0.48 | T = 0.101 | 0.921 |
| TG (mg/dl) | 120 (26–887) | 121.5 (26–887) | 105.5 (62–231) | 131 (98–276) | H = 0.632 | 0.729 | U = 400.0 | 0.684 |
| TC (mg/dl) | 16 7 (80–302) | 169.5 (80–302) | 126 (72–196) | 190 (126–253) | F = 2.821 | 0.044 | T = 2.017 | 0.046 |
| HDL-C (mg/dl) | 30.9 (28.6–37.8) | 36 (25–60) | 30.9 (28.6–37.8) | 36 (28–50) | F = 2.740 | 0.046 | T = 2.225 | 0.028 |
| LDL-C (mg/dl) | 105.6 (30.3–222.4) | 108.9 12.4–222.4) | 70.6 (31–146) | 128.9 (45.2–165.8) | H = 4.131 | 0.127 | U = 507.5 | 0.076 |
| VLDL-C (mg/dl) | 105.6 (30.3–222.4) | 24.3 (5.2–177.4) | 21.1 (12.4–46.2) | 128.9 (45.2–165.8) | H = 0.632 | 0.729 | U = 400.0 | 0.684 |
| Gender | ||||||||
| Male | 52(64.2%) | 58 (63%) | 2 (25%) | 6 (54.5%) | X2 = 4.814 | 0.092 | X2 = 4.438 | 0.057 |
| Female | 29 (35.8%) | 34 (37%) | 6 (75%) | 5 (45.5%) | ||||
| Smoking status | ||||||||
| Absent | 6(75%) | 41 (50.6%) | 7 (63.6%) | 48 (52.2%) | 2.205 | 0.332 | 1.544 | 0.214 |
| Present | 2 (25%) | 40 (49.4%) | 4 (36.4%) | 44 (47.8%) | ||||
OR odds ratio, CI confidence interval, P1 comparison between CT, CC and TT, P2 comparison between CT + TT versus CC, F ANOVA, T student t test, U Mann Whitney test, X2 chi square test.